false
0001321834
0001321834
2026-11-20
2026-11-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 20, 2026
Q/C
Technologies, Inc.
(Exact
name of Registrant as specified in its charter)
| Delaware |
|
001-36268 |
|
22-2983783 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
No.) |
|
(IRS
Employer
Identification
No.) |
| 333 Bush Street, Suite 1400 |
|
|
| San Francisco, CA |
|
94104 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (856) 848-8698
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
Registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
stock, par value $0.001 per share |
|
QCLS |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement
Omnibus
Amendment Agreement
As
previously disclosed, on May 20, 2024, Q/C Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement
(the “Series G Purchase Agreement”) with certain accredited investors (the “Holders”) pursuant to which the Company
issued and sold to the Holders in a private placement (i) shares of the Company’s Series G convertible preferred stock, par value
$0.001 per share (the “Series G Preferred Stock”), (ii) certain warrants to purchase shares of the Company’s common
stock, par value $0.001 per share (the “Common Stock”), with a term of five (5) years from the date of issuance (the “Series
G Long-Term Warrants”), and (iii) warrants to purchase shares of the Company’s Common Stock, with an initial term of eighteen
(18) months from the date of issuance. The terms of the Series G Preferred Stock are set forth in the Certificate of Designations of
Series G Preferred Stock filed with the Secretary of State of the State of Delaware (the “Secretary of State”) on May 21,
2024 (as amended, the “Series G Certificate of Designations”).
As
previously disclosed, on September 2, 2025, the Company entered into a Securities Purchase Agreement (the “Series H Purchase Agreement”)
with the Holders pursuant to which the Company issued and sold to the Holders (i) shares of the Company’s Series H Convertible
Preferred Stock, par value $0.001 per share (the “Series H Preferred Stock”), and (ii) accompanying warrants to purchase
shares of Common Stock (the “Series H Warrants”). The terms of the Series H Preferred Stock are set forth in the Certificate
of Designations of Series H Convertible Preferred Stock filed with the Secretary of State on September 3, 2025 (as amended, the “Series
H Certificate of Designations”).
On
November 20, 2026, the Company entered into an Omnibus Amendment Agreement (the “Omnibus Agreement”) with PharmaCyte Biotech,
Inc. (“PharmaCyte”), which holds at least a majority of the outstanding shares of each of the Series G Preferred Stock and
the Series H Preferred Stock and thereby constitutes the Required Holders (as defined under each of the Series G Certificate of Designations
and the Series H Certificate of Designations). Pursuant to the Omnibus Agreement, PharmaCyte agreed to amend (i) the Series G Certificate
of Designations by filing a Certificate of Amendment (the “Series G Amendment”) with the Secretary of State, (ii) the Series
H Certificate of Designations by filing a Certificate of Amendment (the “Series H Amendment”) with the Secretary of State,
and (iii) the Series G Long-Term Warrants held by PharmaCyte to amend the amendment provisions and the beneficial ownership limitation
provisions contained therein.
Each
of the Series G Amendment and the Series H Amendment amends the amendment provisions as set forth therein and amends the beneficial ownership
limitations with respect to PharmaCyte. On November 20, 2026, the Company filed the Series G Amendment and the Series H Amendment with
the Secretary of State, thereby amending the Series G Certificate of Designations and the Series H Certificate of Designations, respectively.
Each of the Series G Amendment and the Series H Amendment became effective with the Secretary of State upon filing.
The
foregoing descriptions of the Omnibus Agreement, the Series G Amendment, and the Series H Amendment do not purport to be complete and
are qualified in their entirety by reference to the full text of each such document, copies of which are filed as Exhibit 10.1, Exhibit
3.1 and Exhibit 3.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.
Item
3.03 Material Modification to Rights of Security Holders
The
matters described in Item 1.01 of this Current Report on Form 8-K related to the Omnibus Agreement, the Series G Amendment and the Series
H Amendment are incorporated herein by reference.
As
previously disclosed in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission
on November 16, 2026, the Company entered into a Consent and Warrant Exchange Agreement on November 15, 2026 (the “Consent Agreement”)
with PharmaCyte. Under the Consent Agreement, PharmaCyte consented to an amendment to the Series H Certificate of Designations that extends
the maturity date of the Series H Preferred Stock from March 2, 2027 to September 2, 2027 (the “Series H Maturity Amendment”).
On November 20, 2026, the Company filed the Series H Maturity Amendment with the Secretary of State.
The
foregoing description of the Series H Maturity Amendment does not purport to be complete and is qualified in its entirety by reference
to the full text of the Series H Maturity Amendment, a copy of which is filed as Exhibit 3.3 to this Current Report on Form 8-K and incorporated
herein by reference.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
| Exhibit
Number |
|
Description |
| 3.1 |
|
Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock (beneficial ownership limitation). |
| 3.2 |
|
Certificate of Amendment of Certificate of Designations of Series H Convertible Preferred Stock (beneficial ownership limitation). |
| 3.3 |
|
Certificate of Amendment of Certificate of Designations of Series H Convertible Preferred Stock (maturity date amendment). |
| 10.1 |
|
Omnibus Amendment Agreement, dated as of November 20, 2026, by and between Q/C Technologies, Inc. and PharmaCyte Biotech, Inc. |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Q/C
TECHNOLOGIES, INC. |
| |
|
|
| Date:
November 20, 2026 |
By: |
/s/
Joshua Silverman |
| |
Name: |
Joshua
Silverman |
| |
Title: |
Executive
Chairman |